Prospective Study Shows that Therapy Guided by bioTheranostics' CancerTYPE ID® Molecular Test Improves Survival in Cancer of Unknown Primary Patients
10/3/2012 10:02:19 AM
More...
|
bioTheranostics Adds Chief Commercial Officer & VP of Corporate Development
7/25/2012 9:44:07 AM
More...
|
bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer
6/19/2012 10:00:54 AM
More...
|
Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by bioTheranostics' CancerTYPE ID®
6/5/2012 10:28:45 AM
More...
|
bioTheranostics Release: New Studies Demonstrate Clinical Utility and Validity of CancerType ID(R) Molecular Classifier
3/22/2012 9:56:36 AM
More...
|
bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
2/1/2012 9:55:48 AM
More...
|
bioTheranostics' Breast Cancer Index(SM) Shows Clinical Utility in Late Recurrence Prognosis and Identification of Patients Eligible for Breast Conserving Surgery
12/12/2011 10:17:24 AM
More...
|
bioTheranostics' CancerTYPE ID(R) Linked With Improved Clinical Outcome and Longer Survival
11/2/2011 1:47:39 PM
More...
|
bioTheranostics Release: New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
7/27/2011 11:07:07 AM
More...
|
Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at American Society of Clinical Oncology 2011 Annual Meeting
6/7/2011 11:22:19 AM
More...
|
|